Business Context and Reporting Period
This Form 8-K Current Report was filed by SELLAS Life Sciences Group, Inc. on June 1, 2021. The report discloses an update regarding the Company's At-the-Market Offering Program.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, or cash flow data. The specific financial activity reported is:
- Program Capacity: Up to $50.0 million in aggregate gross sale proceeds.
- Shares Sold: 365,825 shares of common stock issued and sold since April 16, 2021.
- Net Proceeds: Approximately $3.81 million (after deducting sales commissions).
Material Changes
The material change reported is the execution of sales under the Controlled Equity Offering SM Sales Agreement entered into with Cantor Fitzgerald & Co. on April 16, 2021. The Company has utilized a portion of the authorized $50.0 million program capacity.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond the standard disclosure of the equity offering. The document focuses solely on the mechanics and results of the recent stock sales.
Investor Verification Checklist
- Verify the remaining capacity under the $50.0 million ATM program ($46.19 million).
- Confirm the average net price per share received from the recent sales.
- Review the latest 10-Q or 10-K for comprehensive liquidity and cash position data not included in this 8-K.
- Check for any subsequent filings regarding further sales under the Cantor Fitzgerald agreement.